[{"uuid": "101ec440-0642-3119-89e3-d0f2f9cfd3bd", "title": "Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/corvus-pharmaceuticals-announces-data-cohort-123000251.html", "providerPublishTime": 1736771400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/yqQjOv2yHq76tbGN3ewzdg--~B/aD0zMzI7dz02MjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/353e78da67c576397cb378e5827159f3", "width": 624, "height": 332, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/9lFSQWc7IKD5DXJ.qKjjxw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/353e78da67c576397cb378e5827159f3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}, {"uuid": "9eb539a4-c630-35b7-ad2b-42e7a2defee4", "title": "We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/were-not-worried-corvus-pharmaceuticals-141850330.html", "providerPublishTime": 1736259530, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}, {"uuid": "819d779c-defc-3658-a39f-dd39c7fd0769", "title": "Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/corvus-pharmaceuticals-present-43rd-annual-210100538.html", "providerPublishTime": 1736283660, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Pik734ZmUmCwL6onA3lPZQ--~B/aD0yNDM7dz0xMTUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a88bc564f455fe7604e4cc6c66207706", "width": 1150, "height": 243, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/upaMLxpYCCqlvmuzDmUm_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a88bc564f455fe7604e4cc6c66207706", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}, {"uuid": "71558e2c-ae1d-3301-90ed-0683fb6b8b48", "title": "Alphabet, Uber downgraded: Wall Street's top analyst calls", "publisher": "The Fly", "link": "https://finance.yahoo.com/news/alphabet-uber-downgraded-wall-streets-143930158.html", "providerPublishTime": 1735828770, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 1200, "height": 628, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IPH9wCP.ftudEFOX7xr1MA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["UBER", "GOOG"]}, {"uuid": "44c769e8-0d8e-3c1f-8de4-b87b17385f25", "title": "Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/corvus-pharma-says-data-atopic-133156964.html", "providerPublishTime": 1734528716, "type": "STORY", "relatedTickers": ["CRVS"]}, {"uuid": "6c4ad302-84c1-3c0e-b7e4-3cfb77b2d494", "title": "Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/why-corvus-pharmaceuticals-stock-trading-182345102.html", "providerPublishTime": 1734546225, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Z68csqcpOK63.ZctLDrHkg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/143e96d428978c08b147a32d6ebb52eb", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n0x9q7vqKm8l4JqCK_eT5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/143e96d428978c08b147a32d6ebb52eb", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}, {"uuid": "d9f54dfc-e719-3afc-b715-7641bc67fbd2", "title": "Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/corvus-pharmaceuticals-announces-interim-data-123000093.html", "providerPublishTime": 1734525000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/hEhnDomPyLIszErEn9z41A--~B/aD01NjI7dz0xMDA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9e9e1da011c5c17ead351f4dc7718fbc", "width": 1006, "height": 562, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n18Zg2_RaeVsdkPdN7YCHQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9e9e1da011c5c17ead351f4dc7718fbc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}, {"uuid": "7fe7b1db-358e-3561-9e36-8a515435b35b", "title": "Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/corvus-pharmaceuticals-announce-interim-data-210100991.html", "providerPublishTime": 1734469260, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Pik734ZmUmCwL6onA3lPZQ--~B/aD0yNDM7dz0xMTUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a88bc564f455fe7604e4cc6c66207706", "width": 1150, "height": 243, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/upaMLxpYCCqlvmuzDmUm_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a88bc564f455fe7604e4cc6c66207706", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}, {"uuid": "4cac09a4-60b6-382c-a2a8-e6552d4eee02", "title": "Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/corvus-crvs-move-heres-why-135004941.html", "providerPublishTime": 1731678604, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/p7XlvorZm6LARMpstyEGHA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "4a9de839-2bb9-3519-bd79-28fcd2769ada", "title": "Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/corvus-pharmaceuticals-inc-crvs-q3-071810141.html", "providerPublishTime": 1731482290, "type": "STORY", "relatedTickers": ["CRVS"]}, {"uuid": "62ef224c-1618-316e-9438-6ef1af489cf6", "title": "Corvus Pharmaceuticals Says Published Soquelitinib Data Highlights Novel Approach to Immunotherapy", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/corvus-pharmaceuticals-says-published-soquelitinib-082730820.html", "providerPublishTime": 1733387250, "type": "STORY", "relatedTickers": ["CRVS"]}, {"uuid": "9673921c-c03d-361c-ba9e-ac6f1f6b4076", "title": "Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/individual-investors-account-50-corvus-120642989.html", "providerPublishTime": 1733918802, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRVS"]}]